Welcome!

News Feed Item

Echo Therapeutics, Inc. Announces Second Quarter 2014 Financial Results and Provides Business Update

40%-50% Monthly Cash Burn Reduction Initiatives Implemented

PHILADELPHIA, Aug. 14, 2014 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced its financial results for the quarter ended June 30, 2014 and provided a business update.  Echo's Quarterly Report on Form 10-Q, as filed with the SEC, is available by visiting the Investors section of Echo's website at www.echotx.com.

Echo also announced today that it has taken steps to substantially reduce operating costs and preserve cash while further focusing its development efforts and resources on implementing key product performance enhancements to its Symphony CGM System. The Company has implemented significant cost reductions across all aspects of its operations in both external spend and workforce, including reductions in general and administrative expenditures, manufacturing, clinical and product development expenditures. At the same time, the Company is exploring a variety of funding alternatives which it believes, together with the cost reduction initiatives, is necessary to permit the Company to ultimately achieve its clinical trial and regulatory approval objectives. In the absence of a financing or strategic transaction, Echo's ability to achieve its previously stated product development timelines will be negatively impacted by the Company's effort to preserve cash and reduce expenses.

Cost reduction measures that were successfully implemented in September 2013 resulted in a 36% decrease in second quarter of 2014 operating expenses compared to the second quarter of 2013. The Company anticipates an additional meaningful decrease in expenses as a result of the most recent cost reduction efforts. As a result of these new initiatives, that include a 35% employee reduction, the monthly burn rate is projected to decrease by 40%-50% as compared to the average monthly burn rate experienced during the first six months of 2014.

"Our management team and Board of Directors believe more than ever in the viability of Symphony and in the positive product development progress made in the past few months; however, it is in the best interests of Echo and its shareholders to take immediate and significant action to adjust our business and operating structure in order to achieve cost savings, preserve cash and deploy capital more efficiently as we continue to make progress toward commercialization. Our focus continues to be prudent with our spending while implementing and testing the key product enhancements for the next generation Symphony CGM System," said Kimberly A. Burke, Echo's Interim CEO, General Counsel and Chief Compliance Officer. "We remain excited about the potential for Symphony as an important tool to improve glycemic control in the critical care setting and we believe that additional market segment and partnership opportunities exist for various demographics. Our SkinPrep technology also offers multi-product opportunities for use as a drug delivery device or in combination with other biosensors to monitor additional analytes."

Other Recent Corporate Updates:

  • In June 2014, Echo's clinical study of Symphony was presented during poster sessions at the 74th Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, California.
  • Stockholders elected Shepard M. Goldberg to the Echo Board of Directors at the 2014 Annual Meeting of Stockholders held on June 19, 2014.
  • Kimberly A. Burke was appointed as Interim Chief Executive Officer (CEO) of Echo effective July 1, 2014. The Board continues to work with a retained executive search firm to hire a well-qualified permanent CEO.
  • Charles T. Bernhardt was appointed by the Echo Board of Directors to serve as Interim Chief Financial Officer (CFO) on July 16, 2014.

Second Quarter 2014 Financial Results

Echo's net loss for the second quarter of 2014 was $3.8 million, or ($0.31) per share, compared to $3.3 million, or ($0.51) per share, for the second quarter of 2013.  Operating loss for the second quarter of 2014 was $3.9 million compared to $6.1 million for the second quarter of 2013.  Research and development expenses were $1.7 million for the second quarter of 2014 compared to $4.0 million in the prior year.  The decrease in research and development expenses is primarily related to decreased development and clinical expenses.  General and administrative expenses were $2.2 million for the second quarter of 2014 versus $2.1 million in the prior year.  A decrease in general and administrative expenses was offset by unanticipated expenses that included costs associated with the proxy contest and annual shareholder meeting and legal expenses.  Echo reported a cash balance of approximately $4.1 million as of June 30, 2014.  

About Echo Therapeutics

Echo Therapeutics is developing the Symphony CGM System as a non-invasive, wireless continuous glucose monitoring system for use initially in the critical care setting. A significant longer-term opportunity may also exist for Symphony to be used in the hospital beyond the critical care setting, as well as in patients with diabetes in the outpatient setting. Echo has also developed its needle-free skin preparation device as a platform technology to allow for enhanced skin permeation that enables extraction of analytes, such as glucose, and enhanced delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts, including the statements about future decreases in expense, corporate objectives, a European product launch and initiation of the FDA pivotal trial, may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's clinical studies, the safety and efficacy of Echo's Symphony CGM System, the failure of future development and preliminary marketing efforts related to Echo's Symphony CGM System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell the Symphony CGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony CGM System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2013, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Christine H. Olimpio   
Director, Investor Relations and Corporate Communications
(215) 717-4104                      

Connect With Us:
- Visit our website at www.echotx.com 
- Follow us on Twitter at www.twitter.com/echotx 
- Join us on Facebook at www.facebook.com/echotx


 

Echo Therapeutics, Inc

Condensed Consolidated Balance Sheets

(Unaudited)



  June 30,

2014


December 31,

2013


ASSETS





Current Assets:





Cash and cash equivalents

$      4,105,954


$      8,055,385


Other current assets

1,228,991


1,319,713


Total current assets

5,334,945


9,375,098


Net property and equipment (including assets under capitalized leases)

1,329,539


1,495,807


Other Assets:





Intangible assets, net of accumulated amortization

9,625,000


9,625,000


Deferred financing costs, net of current portion

2,097,322


2,581,324


Restricted cash and other assets

11,490


12,066


Total other assets

11,733,812


12,218,390


Total assets

$    18,398,296


$    23,089,295







LIABILITIES AND STOCKHOLDERS' EQUITY





Current Liabilities:





Accounts payable

$      1,032,360


$      1,036,320


Current portion of deferred revenue from licensing agreements

76,428


76,428


Derivative warrant liability

586,155


1,119,155


Accrued expenses and other liabilities

884,201


1,412,468


Total current liabilities

2,579,144


3,644,371


Deferred revenue from licensing arrangements, net of current portion

38,214


76,428


Total liabilities

2,617,358


3,720,799


Commitments and contingencies





Stockholders' Equity:





Convertible preferred stock, Series C, D & E

27,496


27,496


Common stock

126,654


117,764


Additional paid-in capital

135,133,217


132,192,648


Accumulated deficit

(119,506,429)


(112,969,412)


Total stockholders' equity

15,780,938


19,368,496


Total liabilities and stockholders' equity

$    18,398,296


$    23,089,295


 

 

Condensed Consolidated Statements of Operations

(Unaudited)


Three Months Ended

June 30,


Six Months Ended

June 30,


2014


2013


2014


2013

Licensing revenue

$ 19,107


$ 22,557


$ 38,214


$ 45,114

Total revenues

19,107


22,557


38,214


45,114









Operating Expenses:








Research and development

1,747,254


4,019,149


3,148,162


7,238,872

Selling, general and administrative

2,187,335


2,098,347


3,475,235


4,397,794

Total operating expenses

3,934,589


6,117,496


6,623,397


11,636,666

Loss from operations

(3,915,482)


(6,094,939)


(6,585,183)


(11,591,552)









Other Income (expense):








Interest income (expense), net

(242,994)


(241,458)


(486,334)


(3,414,156)

Gain on disposals of assets

1500


-


1500


-

Gain on revaluation of derivative warrant liability

393,000


2,995,000


533,000


4,675,986

Other income (expense), net

151,506


2,753,542


48,166


1,261,830

Net loss

$ (3,763,976)


$ (3,341,397)


$ (6,537,017)


$ (10,329,722)

Net loss per common share, basic and diluted

$ (0.31)


$ (0.51)


$ (0.55)


$ (1.73)

Basic and diluted weighted average common shares outstanding

12,070,548


6,594,530


11,965,306


5,987,376









(Reflects 1-for-10 reverse stock split effective June 7, 2013)

 

SOURCE Echo Therapeutics, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
As many know, the first generation of Cloud Management Platform (CMP) solutions were designed for managing virtual infrastructure (IaaS) and traditional applications. But that's no longer enough to satisfy evolving and complex business requirements. In his session at 21st Cloud Expo, Scott Davis, Embotics CTO, explored how next-generation CMPs ensure organizations can manage cloud-native and microservice-based application architectures, while also facilitating agile DevOps methodology. He expla...
SYS-CON Events announced today that Evatronix will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Evatronix SA offers comprehensive solutions in the design and implementation of electronic systems, in CAD / CAM deployment, and also is a designer and manufacturer of advanced 3D scanners for professional applications.
SYS-CON Events announced today that Synametrics Technologies will exhibit at SYS-CON's 22nd International Cloud Expo®, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. Synametrics Technologies is a privately held company based in Plainsboro, New Jersey that has been providing solutions for the developer community since 1997. Based on the success of its initial product offerings such as WinSQL, Xeams, SynaMan and Syncrify, Synametrics continues to create and hone inn...
Cloud Expo | DXWorld Expo have announced the conference tracks for Cloud Expo 2018. Cloud Expo will be held June 5-7, 2018, at the Javits Center in New York City, and November 6-8, 2018, at the Santa Clara Convention Center, Santa Clara, CA. Digital Transformation (DX) is a major focus with the introduction of DX Expo within the program. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive ov...
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
To get the most out of their data, successful companies are not focusing on queries and data lakes, they are actively integrating analytics into their operations with a data-first application development approach. Real-time adjustments to improve revenues, reduce costs, or mitigate risk rely on applications that minimize latency on a variety of data sources. In his session at @BigDataExpo, Jack Norris, Senior Vice President, Data and Applications at MapR Technologies, reviewed best practices to ...
DevOps promotes continuous improvement through a culture of collaboration. But in real terms, how do you: Integrate activities across diverse teams and services? Make objective decisions with system-wide visibility? Use feedback loops to enable learning and improvement? With technology insights and real-world examples, in his general session at @DevOpsSummit, at 21st Cloud Expo, Andi Mann, Chief Technology Advocate at Splunk, explored how leading organizations use data-driven DevOps to close th...
Continuous Delivery makes it possible to exploit findings of cognitive psychology and neuroscience to increase the productivity and happiness of our teams. In his session at 22nd Cloud Expo | DXWorld Expo, Daniel Jones, CTO of EngineerBetter, will answer: How can we improve willpower and decrease technical debt? Is the present bias real? How can we turn it to our advantage? Can you increase a team’s effective IQ? How do DevOps & Product Teams increase empathy, and what impact does empath...
Smart cities have the potential to change our lives at so many levels for citizens: less pollution, reduced parking obstacles, better health, education and more energy savings. Real-time data streaming and the Internet of Things (IoT) possess the power to turn this vision into a reality. However, most organizations today are building their data infrastructure to focus solely on addressing immediate business needs vs. a platform capable of quickly adapting emerging technologies to address future ...
With tough new regulations coming to Europe on data privacy in May 2018, Calligo will explain why in reality the effect is global and transforms how you consider critical data. EU GDPR fundamentally rewrites the rules for cloud, Big Data and IoT. In his session at 21st Cloud Expo, Adam Ryan, Vice President and General Manager EMEA at Calligo, examined the regulations and provided insight on how it affects technology, challenges the established rules and will usher in new levels of diligence arou...
Most technology leaders, contemporary and from the hardware era, are reshaping their businesses to do software. They hope to capture value from emerging technologies such as IoT, SDN, and AI. Ultimately, irrespective of the vertical, it is about deriving value from independent software applications participating in an ecosystem as one comprehensive solution. In his session at @ThingsExpo, Kausik Sridhar, founder and CTO of Pulzze Systems, discussed how given the magnitude of today's application ...
There is a huge demand for responsive, real-time mobile and web experiences, but current architectural patterns do not easily accommodate applications that respond to events in real time. Common solutions using message queues or HTTP long-polling quickly lead to resiliency, scalability and development velocity challenges. In his session at 21st Cloud Expo, Ryland Degnan, a Senior Software Engineer on the Netflix Edge Platform team, will discuss how by leveraging a reactive stream-based protocol,...
Mobile device usage has increased exponentially during the past several years, as consumers rely on handhelds for everything from news and weather to banking and purchases. What can we expect in the next few years? The way in which we interact with our devices will fundamentally change, as businesses leverage Artificial Intelligence. We already see this taking shape as businesses leverage AI for cost savings and customer responsiveness. This trend will continue, as AI is used for more sophistica...
In his session at 21st Cloud Expo, Raju Shreewastava, founder of Big Data Trunk, provided a fun and simple way to introduce Machine Leaning to anyone and everyone. He solved a machine learning problem and demonstrated an easy way to be able to do machine learning without even coding. Raju Shreewastava is the founder of Big Data Trunk (www.BigDataTrunk.com), a Big Data Training and consulting firm with offices in the United States. He previously led the data warehouse/business intelligence and B...
In his general session at 21st Cloud Expo, Greg Dumas, Calligo’s Vice President and G.M. of US operations, discussed the new Global Data Protection Regulation and how Calligo can help business stay compliant in digitally globalized world. Greg Dumas is Calligo's Vice President and G.M. of US operations. Calligo is an established service provider that provides an innovative platform for trusted cloud solutions. Calligo’s customers are typically most concerned about GDPR compliance, application p...